Last updated: 2025.11.07
Welcome to curefachildren.com (the “Website”). This Website is operated by Cure FA Children, a non-profit organization dedicated to supporting research and development of gene therapy programs to find a cure for Friedreich’s Ataxia (“FA”).
By accessing or using this Website, you agree to these Terms & Conditions. If you do not agree, please refrain from using the Website.
- Purpose of the Website
The purpose of this Website is to provide information about Cure FA Children’s mission, activities, and fundraising initiatives. All donations and proceeds are used exclusively to support scientific research related to gene therapy for Friedreich’s Ataxia. Cure FA Children is a non-profit organization; no profits are distributed to individuals or entities.
- Donations
All donations made through this Website go directly and in full to support FA gene therapy research. Donations are non-refundable. If you have questions regarding your donation, please contact us at zardasht@curefachildren.com.
- Privacy and Data Collection
Cure FA Children respects your privacy.
- We do not collect, store, or process any personal information from visitors.
- We do not use cookies, analytics tools, or tracking technologies.
- We do not share any visitor data with third parties because no such data is collected.
If you contact us directly (e.g., via email), any information you provide will be used solely to respond to your inquiry and will not be shared with others.
- Intellectual Property
All text, images, and other materials published on this Website are owned or licensed by Cure FA Children, unless otherwise stated. You may view and share this content for personal, educational, or charitable purposes, provided that proper credit is given and the material is not altered or used for commercial gain.
- External Links
This Website may contain links to external websites for informational purposes. Cure FA Children is not responsible for the content, policies, or practices of any external sites.
- Disclaimer
All information provided on this Website is for general informational purposes only. While we strive for accuracy, Cure FA Children makes no guarantees regarding the completeness or reliability of any information contained herein.
- Limitation of Liability
To the fullest extent permitted by law, Cure FA Children shall not be liable for any damages arising out of or related to the use of this Website or the inability to use it.
- Changes to These Terms
Cure FA Children may update these Terms & Conditions from time to time. Any changes will be posted on this page with a new “Last updated” date. Your continued use of the Website constitutes your acceptance of any revisions.
Is cureFAchildren a company?
No. cureFAchildren is a non-profit organization. No profits are distributed, and all funds are used exclusively for research toward proof of concept.
How are donations used?
Donations are used to fund preclinical research, academic collaborations, and proof of concept activities. No funds are used for commercial purposes or personal compensation.
Will this project become a company?
At this stage, it is not possible to know exactly what the final organizational structure will be. What matters most is that the program continues to move forward and ultimately reaches the children and families who need the treatment.
After successful proof of concept, the next steps involve regulatory toxicology studies, GMP manufacturing, and the initiation of clinical trials. Bringing a gene therapy program from PoC to first-in-human studies typically requires on the order of USD 3–6 million.
However, advancing a therapy all the way through clinical development, regulatory approval, and global access is a much larger undertaking. The total cost to reach full approval by authorities such as the FDA and EMA, and to make the treatment broadly available, often reaches tens to hundreds of millions of US dollars.
There are several possible paths forward at that stage: the program could be advanced through the formation of a dedicated biotech company, through partnership with an established pharmaceutical or biotechnology company, or through other collaborative structures capable of providing the required resources and infrastructure.
The exact route will be determined by what best serves the patients and ensures that the therapy can be developed safely, efficiently, and made accessible to all who need it. The primary goal is not the creation of a company, but the successful translation of this program into a life-saving treatment for children with Friedreich’s ataxia.
Why not start as a company from the beginning?
Early-stage research can be conducted more efficiently, ethically, and cost-effectively within a non-profit and academic framework. This approach reduces risk, maximizes scientific focus, and ensures that donations are used solely to advance the science.
Does this affect donors?
No. Donations support only early-stage research and proof of concept. Any future company would be separately funded and governed.
Contact Us
If you have any questions or concerns about these Terms & Conditions, please contact us at:
📧 zardasht@curefachildren.com
🌐 https://curefachildren.com